Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 291

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 291
---
able common stock resulted in charges against additional paid-in capital and accumulated deficit.

<div align='center'>F-67</div>

As of March 31, 2025 and December 31, 2024, the common stock reflected on the unaudited condensed balance sheets are reconciled in the following table:

| ​                                                                           | ​ | ​ |         ​ |
|:----------------------------------------------------------------------------|:--|:--|----------:|
| Class A common stock subject to possible redemption as of December 31, 2024 |   | $ | 1,756,468 |
| Less: 2024 adjustment to share price for shares redeemed in December 2024   | ​ |   |    -1,826 |
| Less: Shares redeemed in March 2025                                         | ​ |   |  -702,359 |
| Plus: Remeasurement of carrying value to redemption value                   | ​ |   |    37,585 |
| Class A common stock subject to possible redemption as of March 31, 2025    | ​ | $ | 1,089,868 |

Upon the closing of the Business Combination, holders of the Company’s Class A common stock received shares of the combined company’s common stock.

Warrants — Each whole warrant entitles the holder to purchase share of Class A common stock at a price of $ per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $ per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the initial stockholders or their affiliates, without taking into account any Founder Shares held by the initial stockholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than % of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A common stock during the trading day period starting on the trading day after the day on which the Company consummates its initial Business Combination (such price